Renovaro Inc. (NASDAQ:RENB) Short Interest Update

Renovaro Inc. (NASDAQ:RENB) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 5,060,000 shares, an increase of 30.7% from the December 15th total of 3,870,000 shares. Based on an average daily volume of 1,030,000 shares, the days-to-cover ratio is currently 4.9 days. Currently, 6.6% of the shares of the company are short sold.

Renovaro Price Performance

Shares of NASDAQ:RENB traded down $0.04 on Friday, reaching $0.71. The company’s stock had a trading volume of 624,909 shares, compared to its average volume of 1,725,119. Renovaro has a 52-week low of $0.40 and a 52-week high of $5.25. The stock has a market capitalization of $112.22 million, a P/E ratio of -0.74 and a beta of 0.66. The stock’s 50-day moving average is $0.99 and its two-hundred day moving average is $0.84.

Institutional Trading of Renovaro

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC raised its position in Renovaro by 315.7% during the 3rd quarter. Barclays PLC now owns 69,531 shares of the company’s stock worth $34,000 after buying an additional 52,804 shares during the last quarter. State Street Corp raised its holdings in Renovaro by 3.8% during the third quarter. State Street Corp now owns 1,323,832 shares of the company’s stock worth $640,000 after purchasing an additional 48,114 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Renovaro in the second quarter valued at about $220,000. Rhumbline Advisers acquired a new stake in Renovaro in the second quarter valued at about $79,000. Finally, SG Americas Securities LLC boosted its holdings in Renovaro by 193.3% in the 4th quarter. SG Americas Securities LLC now owns 51,725 shares of the company’s stock valued at $43,000 after purchasing an additional 34,090 shares in the last quarter. 71.41% of the stock is owned by hedge funds and other institutional investors.

Renovaro Company Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.